JPMorgan Chase & Co. Lowers Boston Scientific (NYSE:BSX) Price Target to $100.00

Boston Scientific (NYSE:BSX) had its target price lowered by equities research analysts at JPMorgan Chase & Co. from $135.00 to $100.00 in a research report issued on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the medical equipment provider’s stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 28.86% from the stock’s current price.

Several other equities research analysts have also weighed in on the company. Robert W. Baird decreased their price objective on Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a report on Thursday. Stifel Nicolaus reduced their target price on shares of Boston Scientific from $125.00 to $110.00 and set a “buy” rating for the company in a research note on Wednesday. Morgan Stanley lowered their price target on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a research report on Thursday. Royal Bank Of Canada reduced their price objective on shares of Boston Scientific from $130.00 to $115.00 and set an “outperform” rating for the company in a research note on Thursday. Finally, National Bankshares set a $115.00 target price on Boston Scientific in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $109.32.

Boston Scientific Stock Performance

BSX stock traded up $2.10 during mid-day trading on Thursday, hitting $77.60. The company had a trading volume of 37,879,809 shares, compared to its average volume of 16,601,010. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. The firm has a market cap of $115.04 billion, a PE ratio of 41.50, a price-to-earnings-growth ratio of 1.63 and a beta of 0.67. Boston Scientific has a 12 month low of $74.86 and a 12 month high of $109.50. The stock’s fifty day moving average price is $94.37 and its two-hundred day moving average price is $99.13.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The company had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. During the same quarter in the previous year, the firm posted $0.70 EPS. Boston Scientific’s revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, analysts forecast that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the transaction, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. This represents a 42.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. The SEC filing for this sale provides additional information. 0.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in BSX. iA Global Asset Management Inc. lifted its holdings in shares of Boston Scientific by 1.1% in the 4th quarter. iA Global Asset Management Inc. now owns 206,183 shares of the medical equipment provider’s stock worth $19,660,000 after acquiring an additional 2,259 shares during the last quarter. May Hill Capital LLC lifted its stake in Boston Scientific by 99.2% in the fourth quarter. May Hill Capital LLC now owns 72,576 shares of the medical equipment provider’s stock worth $6,920,000 after purchasing an additional 36,143 shares during the last quarter. Beese Fulmer Investment Management Inc. boosted its position in Boston Scientific by 4,839.4% during the fourth quarter. Beese Fulmer Investment Management Inc. now owns 222,026 shares of the medical equipment provider’s stock valued at $21,170,000 after buying an additional 217,531 shares during the period. Canada Post Corp Registered Pension Plan grew its stake in shares of Boston Scientific by 6.7% during the fourth quarter. Canada Post Corp Registered Pension Plan now owns 57,803 shares of the medical equipment provider’s stock valued at $5,512,000 after buying an additional 3,606 shares during the last quarter. Finally, Dana Investment Advisors Inc. grew its stake in shares of Boston Scientific by 12.8% during the fourth quarter. Dana Investment Advisors Inc. now owns 146,537 shares of the medical equipment provider’s stock valued at $13,972,000 after buying an additional 16,674 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 results beat consensus — BSX reported $0.80 EPS (vs. ~$0.78 expected) and $5.29B revenue with ~16% year‑over‑year sales growth, underpinning the company’s operational momentum. Boston Scientific announces results for fourth quarter and full year 2025
• Positive Sentiment: Long‑term case still cited by analysts and research services highlighting BSX as a growth company — supports investors focused beyond the near‑term guidance miss. Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
• Neutral Sentiment: Analysts trimmed price targets after Q4/guidance — several firms cut PTs (but maintained buy/overweight ratings), leaving mixed messages: lowered near‑term expectations but continued conviction in medium‑term upside. Boston Scientific Analysts Cut Their Forecasts Following Q4 Results
• Neutral Sentiment: Unusually active options and heavy put buying indicate elevated short‑term hedging/speculation — a sign volatility may persist regardless of fundamentals. Don’t Miss Out: Strangle Plays on These 3 Top 25 Unusually Active Options Gems!
• Negative Sentiment: Cautious 2026 guidance was the primary catalyst for the sell‑off — revenue and EPS ranges were modest and landed at or just under Street expectations, prompting investors to reset growth assumptions. Boston Scientific shares slide on cautious 2026 revenue forecast
• Negative Sentiment: Following the guidance, the stock experienced a high‑volume liquidation that erased months of gains and sent shares sharply lower — a technical unwind that can amplify short‑term downside. What Happened To Boston Scientific Stock?
• Negative Sentiment: A securities‑fraud investigation notice from a plaintiff firm (Levi & Korsinsky) introduces legal/PR risk that could prolong volatility if it gains traction. Investors in Boston Scientific Corporation (BSX) Warned of Potential Securities Fraud – Contact Levi & Korsinsky Today
• Negative Sentiment: Large insider sale disclosed — CEO sold ~160,901 shares in early February, a disclosure investors may interpret as a negative signal during an already sensitive period. Insider Selling: Boston Scientific (NYSE:BSX) CEO Sells 160,901 Shares of Stock

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.